Molecular Target Synopsis
Overview
Domains and Structures
Drugs and Clinical Candidates
Druggability
Chemistry
Ligand Efficiency Plot
Pathways
Family Cladogram
Interaction Network
Gene Expression
Gene Copy Number Variation
RNAi
Mutations
Germline Genetics

SLC17A3 (O00476) - Overview - Molecular Target Synopsis

Protein


SLC17A3, Sodium-dependent phosphate transport protein 4
UniProt O00476

Also Known as NPT4_HUMAN, SLC17A3, NPT4

Isoform 2: voltage-driven, multispecific, organic anion transporter able to transport para-aminohippurate (PAH), estrone sulfate, estradiol-17-beta-glucuronide, bumetanide, and ochratoxin A. Isoform 2 functions as urate efflux transporter on the apical side of renal proximal tubule and is likely to act as an exit path for organic anionic drugs as well as urate in vivo. May be involved in actively transporting phosphate into cells via Na(+) cotransport.

Isoforms / Transcripts (Protein Coding)


Sub-cellular localization


UniProt: SLC17A3 is active in the following subcellular-locations: cell membrane, endoplasmic reticulum membrane.
GO terms: SLC17A3 is active in the following subcellular-locations: apical plasma membrane, brush border membrane, cytoplasm, endoplasmic reticulum membrane, integral component of membrane, integral component of plasma membrane, lysosome, perinuclear region of cytoplasm, plasma membrane.



UniProt
GO terms

Gene Copy Number Variation


In COSMIC - Cell Lines Project SLC17A3 has gain in 3 cell-lines, loss in 1 cell-lines and no signal in 1001 cell-lines. (see details)

Gene Expression


In NCI60, the highest expressing cell lines are: ACHN, LOXIMVI, UACC_62

In Array Express (RNA-seq of 675 commonly used human cancer cell lines), the highest expressing cell lines are: 769-P, ACHN, OVTOKO

In Array Express (RNA-seq of long poly adenylated RNA and long non poly adenylated RNA from ENCODE cell lines), the highest expressing cell lines are: SK-N-SH, NHLF, HSMM

(see details)


Screening and Chemistry


SLC17A3 has been screened with compounds ( bioactivities). (see details)